Roberts S - Search Results

1

Noninvasive Assessment of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract After Allogeneic Hemopoietic Stem Cell Transplantation Using ¹⁸F-FDG PET.

Cherk MH, Khor R, Barber TW, Yap KSK, Patil S, Walker P, Avery S, Roberts S, Kemp W, Pham A, Bailey M, Kalff V. Cherk MH, et al. Among authors: roberts s. J Nucl Med. 2022 Dec;63(12):1899-1905. doi: 10.2967/jnumed.121.263688. Epub 2022 Apr 21. J Nucl Med. 2022. PMID: 35450959 Free article.

2

Urotensin II: a vascular mediator in health and disease.

Kemp W, Roberts S, Krum H. Kemp W, et al. Among authors: roberts s. Curr Vasc Pharmacol. 2005 Apr;3(2):159-68. doi: 10.2174/1570161053586930. Curr Vasc Pharmacol. 2005. PMID: 15853635 Review.

3

Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patients with cystic fibrosis before and after lung transplantation.

Button BM, Roberts S, Kotsimbos TC, Levvey BJ, Williams TJ, Bailey M, Snell GI, Wilson JW. Button BM, et al. Among authors: roberts s. J Heart Lung Transplant. 2005 Oct;24(10):1522-9. doi: 10.1016/j.healun.2004.11.312. J Heart Lung Transplant. 2005. PMID: 16210125

4

Increased circulating urotensin II in cirrhosis: potential implications in liver disease.

Kemp W, Roberts S, Krum H. Kemp W, et al. Among authors: roberts s. Peptides. 2008 May;29(5):868-72. doi: 10.1016/j.peptides.2007.08.020. Epub 2007 Aug 25. Peptides. 2008. PMID: 17913301 Review.

5

Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension.

Kemp W, Krum H, Colman J, Bailey M, Yandle T, Richards M, Roberts S. Kemp W, et al. Among authors: roberts s. Liver Int. 2007 Nov;27(9):1232-9. doi: 10.1111/j.1478-3231.2007.01539.x. Liver Int. 2007. PMID: 17919235

6

Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial.

Kemp W, Colman J, Thompson K, Madan A, Vincent M, Chin-Dusting J, Kompa A, Krum H, Roberts S. Kemp W, et al. Among authors: roberts s. Liver Int. 2009 Mar;29(3):427-33. doi: 10.1111/j.1478-3231.2008.01850.x. Epub 2008 Jul 29. Liver Int. 2009. PMID: 18673434 Clinical Trial.

7

Urotensin II in chronic liver disease: in vivo effect on vascular tone.

Kemp W, Roberts S, Komesaroff PA, Zomer E, Krum H. Kemp W, et al. Among authors: roberts s. Scand J Gastroenterol. 2008 Jan;43(1):103-9. doi: 10.1080/00365520701580009. Scand J Gastroenterol. 2008. PMID: 18938752

8

Minimally invasive prediction of esophageal varices and portal hypertension.

Kemp W, Roberts S. Kemp W, et al. Among authors: roberts s. J Gastroenterol Hepatol. 2009 Sep;24(9):1480-1. doi: 10.1111/j.1440-1746.2009.06000.x. J Gastroenterol Hepatol. 2009. PMID: 19743993 No abstract available.

9

Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats.

Kemp W, Kompa A, Phrommintikul A, Herath C, Zhiyuan J, Angus P, McLean C, Roberts S, Krum H. Kemp W, et al. Among authors: roberts s. Am J Physiol Gastrointest Liver Physiol. 2009 Oct;297(4):G762-7. doi: 10.1152/ajpgi.00127.2009. Am J Physiol Gastrointest Liver Physiol. 2009. PMID: 19797237 Free article.

10

Urotensin II levels are an important marker for the severity of portal hypertension in children.

Pawar R, Kemp W, Roberts S, Krum H, Yandle T, Hardikar W. Pawar R, et al. Among authors: roberts s. J Pediatr Gastroenterol Nutr. 2011 Jul;53(1):88-92. doi: 10.1097/MPG.0b013e3182153900. J Pediatr Gastroenterol Nutr. 2011. PMID: 21694541

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,821 results

Search Page